Eyenuk
Is this your brand? Claim it — free, and takes a minute with your work email.
Overview
Tagline Brand's website · 2026-10-04
Eyenuk's EyeArt is the first and only FDA 510(k)-cleared autonomous AI for simultaneous detection of mtmDR and vtDR, boasting high accuracy (96% sensitivity, 88% specificity for mtmDR; 97% sensitivity, 90% specificity for vtDR). It's a multidisease platform expanding to detect AMD, glaucoma, and predictive biomarkers, is compatible with multiple retinal camera models, and operates without typically needing patient dilation.
Description Brand's website · 2026-10-04
Eyenuk provides the first and only FDA 510(k)-cleared autonomous AI (powered by EyeArt) that detects vision-threatening diabetic retinopathy. The solution offers immediate health insights through non-invasive retinal imaging, designed for early detection, triage, and monitoring of eye diseases like DR, AMD, and glaucomatous signs without requiring specialists for initial screening.
Offerings
Core capabilities Brand's website · 2026-10-04
- EyeArt
- an autonomous AI system for retinal screening that detects more than mild and vision-threatening diabetic retinopathy (mtmDR/vtDR)
- Age-related Macular Degeneration (AMD)
- and glaucomatous signs.
Pricing Brand's website · 2026-10-04
The system enables healthcare providers to generate immediate revenue by billing CPT 92229 for autonomous, specialist-free AI retinal screening, aligning with value-based care models.
Audience
Target industry Brand's website · 2026-10-04
Healthcare providers including primary care, endocrinology, optometry, ophthalmology, and large public health screening programs. It serves clinical settings in the US and globally.
Is this your business?
The information above is publicly sourced — assembled by Optimly from Eyenuk's website and public pages.
Claim this profile to publish your own verified Business Profile and speak for Eyenuk across the index.
Claim Eyenuk — free →Page last updated 2026-10-17.